FrenvasTM is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, triglycerides (TG).
FrenvasTM is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3- hydroxy- 3- methyl- glutaryl- coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Triglycerides (TG) and cholesterol in the liver are incorporated into VLDL and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolised primarily through the high affinity LDL receptor. FrenvasTM lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. FrenvasTM reduces LDL production and the number of LDL particles. FrenvasTM produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles